|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0011306,
umls-concept:C0012854,
umls-concept:C0013126,
umls-concept:C0301872,
umls-concept:C0302350,
umls-concept:C1155065,
umls-concept:C1456820,
umls-concept:C1515655,
umls-concept:C1516349,
umls-concept:C1533691,
umls-concept:C2349975
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2000-12-7
|
|
pubmed:abstractText |
Dendritic cells (DC) manipulated ex vivo can induce tumor immunity in experimental murine tumor models. To improve DC-based tumor vaccination, we studied whether DC maturation affects the T cell-activating potential in vitro and the induction of tumor immunity in vivo. Maturation of murine bone marrow-derived DC was induced by GM-CSF plus IL-4 alone or by further addition of TNF-alpha or a cytidine-phosphate-guanosine (CpG)-containing oligonucleotide (ODN-1826), which mimics the immunostimulatory effect of bacterial DNA. Flow cytometric analysis of costimulatory molecules and MHC class II showed that DC maturation was stimulated most by ODN-1826, whereas TNF-alpha had an intermediate effect. The extent of maturation correlated with the secretion of IL-12 and the induction of alloreactive T cell proliferation. In BALB/c mice, s.c. injection of colon carcinoma cells resulted in rapidly growing tumors. In this model, CpG-ODN-stimulated DC cocultured with irradiated tumor cells also induced prophylactic protection most effectively and were therapeutically effective when administered 3 days after tumor challenge. Thus, CpG-ODN-enhanced DC maturation may represent an efficient means to improve clinical tumor vaccination.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0022-1767
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
165
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
6278-86
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11086063-Adjuvants, Immunologic,
pubmed-meshheading:11086063-Animals,
pubmed-meshheading:11086063-Antineoplastic Agents,
pubmed-meshheading:11086063-Cell Communication,
pubmed-meshheading:11086063-Cell Differentiation,
pubmed-meshheading:11086063-Cells, Cultured,
pubmed-meshheading:11086063-Coculture Techniques,
pubmed-meshheading:11086063-Colonic Neoplasms,
pubmed-meshheading:11086063-CpG Islands,
pubmed-meshheading:11086063-Dendritic Cells,
pubmed-meshheading:11086063-Female,
pubmed-meshheading:11086063-Growth Inhibitors,
pubmed-meshheading:11086063-Immunotherapy, Adoptive,
pubmed-meshheading:11086063-Interleukin-12,
pubmed-meshheading:11086063-Interleukin-4,
pubmed-meshheading:11086063-Lymphocyte Activation,
pubmed-meshheading:11086063-Mice,
pubmed-meshheading:11086063-Mice, Inbred BALB C,
pubmed-meshheading:11086063-Mice, Inbred C57BL,
pubmed-meshheading:11086063-Neoplasm Transplantation,
pubmed-meshheading:11086063-Oligodeoxyribonucleotides,
pubmed-meshheading:11086063-T-Lymphocytes,
pubmed-meshheading:11086063-Tumor Cells, Cultured,
pubmed-meshheading:11086063-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo.
|
|
pubmed:affiliation |
Divisions of. Clinical Pharmacology and Neuroendocrinology, Departments of Medicine and Radiation Therapy, Ludwig-Maximilians-University of Munich, Munich, Germany.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
